Description: Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Home Page: www.ascletis.com
Building D
Hangzhou,
311200
China
Phone:
86 571 8538 9730
Officers
| Name | Title |
|---|---|
| Dr. Jinzi Jason Wu Ph.D. | Founder, Chairman & CEO |
| Ms. Hejingdao Wu | Senior VP of Operations & Executive Director |
| Ms. Yuemei Yan | Senior Vice President of Clinical Development Operations |
| Dr. Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery |
| Dr. George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor |
| Mr. John P. Gargiulo M.B.A. | Chief Business Officer |
| Mr. Ming Fai Chung CPA | Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6751 |
| Price-to-Sales TTM: | 20.2661 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 219 |